Neurodegeneration and Neuroprotection in Parkinson Disease

NeuroRx

Volumn 1, Issue 1, 2004, Pages 139-154

  Fahn, Stanley ^a   Sulzer, David ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

alpha synuclein; PARK genes; Parkin gene; ubiquitin pathway

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; ALPHAPRODINE; CATECHOLAMINE; CEP 1347; CREATINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; MANGANESE; MINOCYCLINE; NEUROMELANIN; PARKIN; PETHIDINE; PLACEBO; RILUZOLE; ROTENONE; SELEGILINE; UBIDECARENONE; NEUROPROTECTIVE AGENT;

ANOREXIA; ARTICLE; CATECHOLAMINE NERVE CELL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE MUTATION; GLIOSIS; HEREDITY; HUMAN; INFLAMMATION; INTOXICATION; LEWY BODY; MONOTHERAPY; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PARESTHESIA; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; SIDE EFFECT; SUBSTANTIA NIGRA; VIRAL GENE THERAPY; VOMITING; WEIGHT REDUCTION; ANIMAL; BRAIN; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BRAIN; CLINICAL TRIALS; HUMANS; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 3543056130     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.1.139     Document Type: Article

References (158)

1. Fahn S., and Przedborski S. Parkinsonism. In: Rowland L. (Ed). Merritt's neurology (2000), Lippincott Williams & Wilkins, Philadelphia 679-693
2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 991 (2003) 1-14
3. Seibyl J., Marek K., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38 (1995) 589-598
4. Eidelberg D., Moeller J., Ishikawa T., Dhawan V., Spetsieris P., Chaly T., et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 36 (1995) 378-383
5. Snow B., Lee C., Schulzer M., Mak E., and Calne D. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism. Ann Neurol 36 (1994) 759-764
6. Morrish P., Sawle G., and Brooks D. An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119 (1996) 585-591
7. Benamer H., Patterson J., Wyper D., Hadley D., Macphee G., and Grosset D. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15 (2000) 692-698
8. Mayeux R., Marder K., Cote L., Denaro J., Hemenegildo N., Mejia H., et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 142 (1995) 820-827
9. de Rijk M., Tzourio C., Breteler M., Dartigues J., Amaducci L., Lopez-Pousa S., et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62 (1997) 10-15
10. Bower J., Maraganore D., McDonnell S., and Rocca W. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 15 (2000) 819-825
11. Twelves D., Perkins K., and Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 18 (2003) 19-31
12. Baldereschi M., Di Carlo A., Rocca W., Vanni P., Maggi S., Perissinotto E., et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55 (2000) 1358-1363
13. Diederich N., Moore C., Leurgans S., Chmura T., and Goetz C. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 60 (2003) 529-533
14. Kish S., Shannak K., Rajput A., Deck J., and Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 58 (1992) 642-648
15. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F., and Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 26 (1989) 551-557
16. Booij J., Bergmans P., Winogrodzka A., Speelman J., and Wolters E. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 39 (2001) 101-108
17. Kubis N., Faucheux B., Ransmayr G., Damier P., Duyckaerts C., Henin D., et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123 (2000) 366-373
18. Fearnley J., and Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
19. Zeiring A., Berger L., Heineman S., and Lee J. Piperidine derivatives. Part III. 4-arylpiperidines. J Org Chem 12 (1947) 894-903
20. Schmidle C., and Mansfield R. The aminomethylation of olefins. IV. The formation of 1-alkyl-4-aryl-1.2.3.6-tetrahydropyridines. Am J Chem 78 (1955) 425-428
21. Davis G., Williams A., Markey S., Ebert M., Caine E., Reichert C., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1 (1979) 249-254
22. Wright J., Wall R., Perry T., and Paty D. Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis. N Engl J Med 310 (1984) 325
23. Langston J., and Ballard P. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 309 (1983) 310
24. Langston J., Ballard P., Tetrud J., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
25. Langston J., and Palfreman J. The case of the frozen addicts (1995), Pantheon Books, New York
26. Burns R., Chiueh C., Markey S., Ebert M., Jacobowitz D., and Kopin I. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methl-4-phenyl-1,2,36-tetrahydropyridine. Proc Natl Acad Sci USA 80 (1983) 4546-4550
27. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327 (1992) 1556-1563
28. Mena I., Court J., Fuenzalida S., Papavasiliou P., and Cotzias G. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med 282 (1970) 5-10
29. Cook D., Fahn S., and Brait K. Chronic manganese intoxication. Arch Neurol 30 (1974) 59-64
30. Huang C., Chu N., Lu C., Wang J., Tsai J., Tzeng J., et al. Chronic manganese intoxication. Arch Neurol 46 (1989) 1104-1106
31. Tanner C. Epidemiology of Parkinson's disease. Neurol Clin 10 (1992) 317-329
32. Betarbet R., Sherer T., MacKenzie G., Garcia-Osuna M., Panov A., and Greenamyre J. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
33. Hernan M., Takkouche B., Caamano-Isorna F., and Gestal-Otero J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52 (2002) 276-284
34. Tanner C., Ottman R., Goldman S., Ellenberg J., Chan P., Mayeux R., et al. Parkinson disease in twins: an etiologic study. JAMA 281 (1999) 341-366
35. Polymeropoulos M., Lavedan C., Leroy E., Ide S., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
36. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 (1998) 106-108
37. Spillantini M., Schmidt M., Lee V., Trojanowski J., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
38. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90 (1993) 11282-11286
39. Engelender S., Kaminsky Z., Guo X., Sharp A., Amaravi R., Kleiderlein J., et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22 (1999) 110-114
40. Uversky V., Li J., Bower K., and Fink A. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology 23 (2002) 527-536
41. Conway K., Rochet J., Bieganski R., and Lansbury Jr. P. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
42. Yamin G., Glaser C., Uversky V., and Fink A. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem 16 (2003) 16
43. Paxinou E., Chen Q., Weisse M., Giasson B., Norris E., Rueter S., et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21 (2001) 8053-8061
44. Cole N., and Murphy D. The cell biology of alpha-synuclein: a sticky problem?. Neuromolecular Med 1 (2002) 95-109
45. Clayton D., and George J. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21 (1998) 249-254
46. Maroteaux L., Campanelli J., and Scheller R. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8 (1988) 2804-2815
47. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W., Verdugo J., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
48. Cabin D., Shimazu K., Murphy D., Cole N., Gottschalk W., McIlwain K., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22 (2002) 8797-8807
49. Murphy D., Rueter S., Trojanowski J., and Lee V. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20 (2000) 3214-3220
50. Perez R., Waymire J., Lin E., Liu J., Guo F., and Zigmond M. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22 (2002) 3090-3099
51. Lee F., Liu F., Pristupa Z., and Niznik H. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15 (2001) 916-926
52. Singleton A., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., et al. Alpha-synuclein locus triplication in PD. Science 302 (2003) 841
53. Dauer W., Kholodilov N., Vila M., Trillat A., Goodchild R., Larsen K., et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99 (2002) 14524-14529
54. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H., and Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 277 (2002) 38884-38894
55. Shimura H., Schlossmacher M., Hattori N., Frosch M., Trockenbacher A., Schneider R., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
56. Webb J., Ravikumar B., Atkins J., Skepper J., and Rubinsztein D. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 28 (2003) 25009-25013
57. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
58. Lucking C., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342 (2000) 1560-1567
59. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50 (2001) 293-300
60. Foroud T., Uniacke S., Liu L., Pankratz N., Rudolph A., Halter C., et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60 (2003) 796-801
61. Zhang Y., Gao J., Chung K., Huang H., Dawson V., and Dawson T. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97 (2000) 13354-13359
62. Staropoli J., McDermott C., Martinat C., Schulman B., Demireva E., and Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37 (2003) 735-749
63. Petrucelli L., O'Farrell C., Lockhart P., Baptista M., Kehoe K., Vink L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein. Neuron 36 (2002) 1007-1019
64. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., et al. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
65. Bonifati V., Rizzu P., van Baren M., Schaap O., Breedveld G., Krieger E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
66. Su H., and Li S. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 296 (2002) 65-73
67. Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S., and Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem 276 (2001) 37556-37563
68. Mitsumoto A., Nakagawa Y., Takeuchi A., Okawa K., Iwamatsu A., and Takanezawa Y. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 35 (2001) 301-310
69. Johnston J., Ward C., and Kopito R. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143 (1998) 1883-1898
70. Lee H., and Lee S. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 277 (2002) 48976-48983
71. Junn E., Lee S., Suhr U., and Mouradian M. Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 277 (2002) 47870-47877
72. Volles M., Lee S., Rochet J., Shtilerman M., Ding T., Kessler J., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
73. Javitch J., and Snyder S. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106 (1984) 455-456
74. Gainetdinov R., Fumagalli F., and Caron M. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69 (1997) 1322-1325
75. Fumagalli F., Gainetdinov R., Valenzano K., and Caron M. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18 (1998) 4861-4869
76. Ramsay R., Salach J., and Singer T. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun 134 (1986) 743-748
77. Nicklas W., Youngster S., Kindt M., and Heikkila R. MPTP, MPP+ and mitochondrial function. Life Sci 40 (1987) 721-729
78. Seutin V., Shen K., North R., and Johnson S. Sulfonylurea-sensitive potassium current evoked by sodium-loading in rat midbrain dopamine neurons. Neuroscience 71 (1996) 709-719
79. Pothos E., Mosharov E., Liu K., Setlik W., Baldini G., Gershon M., et al. Stimulation-dependent regulation of secretory vesicle pH, volume, and quantal size. J Physiol (Lond) 542 (2002) 453-476
80. Przedborski S., Jackson-Lewis V., Muthane U., Jiang H., Ferreira M., Naini A.-B., and Fahn S. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34 (1993) 715-723
81. Gluck M., Ehrhart J., Jayatilleke E., and Zeevalk G. Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides. J Neurochem 82 (2002) 66-74
82. Przedborski S., Chen Q., Vila M., Giasson B., Djaldatti R., Vukosavic S., et al. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem 76 (2001) 637-640
83. Blanchard-Fillion B., Souza J., Friel T., Jiang G., Vrana K., Sharov V., et al. Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J Biol Chem 276 (2001) 46017-46023
84. Miller F., Heffner T., Kotake C., and Seiden L. Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of brain dopamine depletion. Brain Res 229 (1981) 123-132
85. Cubells J., Rayport S., Rajendran G., and Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14 (1994) 2260-2271
86. Giovanni A., Liang L., Hastings T., and Zigmond M. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J Neurochem 64 (1995) 1819-1825
87. Sulzer D., and Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5 (1990) 797-808
88. Hastings T., and Berman S. Dopamine-induced toxicity and quinone modification of proteins: implications for Parkinson's disease. In: Creveling C. (Ed). Role of catechol quinone species in cellular toxicity (1999), F. P. Graham, Johnson City, TN 69-89
89. Sulzer D., and Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotoxicity Res 1 (2000) 181-195
90. Graham D. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14 (1978) 633-643
91. Whitehead R., Ferrer J., Javitch J., and Justice J. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 76 (2001) 1242-1251
92. Lotharius J., and O'Malley K. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium (MPP+) triggers intracellular dopamine oxidation: a novel mechanism of toxicity. J Biol Chem 275 (2000) 38581-38588
93. Davidson C., Gow A., Lee T., and Ellinwood E. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36 (2001) 1-22
94. Matthews R., Yang L., and Beal M. S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp Neurol 143 (1997) 282-286
95. Zecca L., Tampellini D., Gatti A., Crippa R., Eisner M., Sulzer D., et al. The neuromelanin of human substantia nigra and its interaction with metals. J Neural Transm 109 (2002) 663-672
96. Berg D., Gerlach M., Youdim M., Double K., Zecca L., Riederer P., et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79 (2001) 225-236
97. Sulzer D., Bogulavsky J., Larsen K., Behr G., Karatekin E., Kleinman M., et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 97 (2000) 11869-11874
98. Larsen K., and Sulzer D. Autophagy in neurons: a review. Histol Histopathol 17 (2002) 897-908
99. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G., Eisenberg D., et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70 (1992) 539-551
100. Pothos E., Larsen K., Krantz D., Liu Y.-J., Edwards R., and Sulzer D. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 20 (2000) 7297-7306
101. Larsen K., Fon E., LaVoie M., Hastings T., Edwards R., and Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons occurs via autophagy triggered by elevated cytosolic dopamine. J Neurosci 22 (2002) 8951-8960
102. Fumagalli F., Gainetdinov R., Wang Y., Valenzano K., Miller G., and Caron M. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19 (1999) 2424-2431
103. Gainetdinov R., Fumagalli F., Wang Y., Jones S., Levey A., Miller G., et al. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70 (1998) 1973-1978
104. Cookson M. Pathways to Parkinsonism. Neuron 37 (2003) 7-10
105. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by pael-R in Drosophila. Neuron 37 (2003) 911-924
106. Ribeiro C., Carneiro K., Ross C., Menezes J., and Engelender S. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J Biol Chem 277 (2002) 23927-23933
107. Stefanis L., Larsen K., Rideout H., Sulzer D., and Greene L. Expression of A53T mutant, but not wild-type, α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21 (2001) 9549-9560
108. Cuervo A., and Dice J. Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med 76 (1998) 6-12
109. Iacopino A., Christakos S., German D., Sonsalla P., and Altar C. Calbindin-D28K-containing neurons in animal models of neurodegeneration: possible protection from excitotoxicity. Brain Res Mol Brain Res 13 (1992) 251-261
110. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N., and Edwards R. Differential expression of two vesicular monoamine transporters. J Neurosci 15 (1995) 6179-6188
111. Staal R., Hogan K., Liang C., German D., and Sonsalla P. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 293 (2000) 329-335
112. Liss B., Neu A., and Roeper J. The weaver mouse gain-of-function phenotype of dopaminergic midbrain neurons is determined by coactivation of wvGirk2 and K-ATP channels. J Neurosci 19 (1999) 8839-8848
113. Burke R., Antonelli M., and Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J Neurochem 71 (1998) 517-525
114. Offen D., Elkon H., and Melamed E. Apoptosis as a general cell death pathway in neurodegenerative diseases. J Neural Transm Suppl 58 (2000) 153-166
115. Przedborksi S., and Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res 1 (2001) 407-418
116. Vila M., Jackson-Lewis V., Guegan C., Wu D., Teismann P., Choi D., et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol 14 (2001) 483-489
117. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., and Lucius R. Activation of microglia by human neuromelanin is NF-κB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 17 (2003) 500-502
118. Teismann P., Tieu K., Choi D., Wu D., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100 (2003) 5473-5478
119. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321 (1989) 1364-1371
120. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 (1993) 176-183
121. Myllyla V., Sotaniemi K., Vuorinen J., and Heinonen E. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42 (1992) 339-343
122. Palhagen S., Heinonen E., Hagglund J., Kaugesaar T., Kontants H., Maki-Ikola O., et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 51 (1998) 520-525
123. Giladi N., McDermott M., Fahn S., Przedborski S., Jankovic J., Stern M., et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56 (2001) 1712-1721
124. Shoulson I., Oakes D., Fahn S., Lang A., Langston J., LeWitt P., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 (2002) 604-612
125. Beal M. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 44 (1998) S110-S114
126. Benazzouz A., Boraud T., Dubedat P., Boireau A., Stutzmann J., and Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284 (1995) 299-307
127. Barneoud P., Mazadier M., Miquet J., Parmentier S., Dubedat P., Doble A., et al. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 74 (1996) 971-983
128. Boireau A., Dubedat P., Bordier F., Imperato A., and Moussaoui S. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 39 (2000) 1016-1020
129. Obinu M., Reibaud M., Blanchard V., Moussaoui S., and Imperato A. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Mov Disord 17 (2002) 13-19
130. Jankovic J., and Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 8 (2002) 271-276
131. Rascol O., Olanow W., Brooks D., Koch G., Truffinet P., and Bejuit R. Effect of riluzole on Parkinson's disease progression: a double-blind placebo-controlled study. Neurology 60 Suppl 1 (2003) A288
132. Pothos E., Davila V., and Sulzer D. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J Neurosci 18 (1998) 4106-4118
133. Gash D., Zhang Z., Ovadia A., Cass W., Yi A., Simmerman L., et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 21 (1996) 252-255
134. Grondin R., Zhang Z., Yi A., Cass W., Maswood N., Andersen A., et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125 (2002) 2191-2201
135. Nutt J., Burchiel K., Comella C., Jankovic J., Lang A., Laws Jr. E., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 (2003) 69-73
136. Gill S., Patel N., O'Sullivan K., Brooks D., Hotton G., Svendsen C., et al. Intraparenchymal putaminal administration of glial-derived neurotrophic factor in the treatment of advanced Parkinson's disease. Neurology 58 Suppl 3 (2002) A241
137. Kordower J., Emborg M., Bloch J., Ma S., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
138. Steiner J., Hamilton G., Ross D., Valentine H., Guo H., Connolly M., et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 94 (1997) 2019-2024
139. Guo X., Dawson V., and Dawson T. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 13 (2001) 1683-1693
140. Tanaka K., Fujita N., Yoshioka M., and Ogawa N. Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing glutathione levels in NG108-15 cells. Brain Res 889 (2001) 225-228
141. Tanaka K., Yoshioka M., Miyazaki I., Fujita N., and Ogawa N. GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum. Neurosci Lett 321 (2002) 45-48
142. Harper S., Bilsland J., Young L., Bristow L., Boyce S., Mason G., et al. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience 88 (1999) 257-267
143. Bocquet A., Lorent G., Fuks B., Grimee R., Talaga P., Daliers J., et al. Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. Eur J Pharmacol 415 (2001) 173-180
144. Emborg M., Shin P., Roitberg B., Sramek J., Chu Y., Stebbins G., et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol 168 (2001) 171-182
145. Eberling J., Pivirotto P., Bringas J., Steiner J., Kordower J., Chu Y., et al. The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp Neurol 178 (2002) 236-242
146. Schapira A., Mann V., Cooper J., Dexter D., Daniel S., Jenner P., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55 (1990) 2142-2145
147. Shults C., Haas R., Passov D., and Beal M. Coenzyme Q(10) levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42 (1997) 261-264
148. Matsubara T., Azuma T., Yoshida S., and Yamagami T. Serum coenzyme Q10 level in Parkinson syndrome. In: Folkers K., Littarru G., and Yamagami T. (Eds). Biomedical and clinical aspects of coenzyme Q10 (1991), Elsevier Science, New York 159-166
149. Matthews R., Yang L., Browne S., Baik M., and Beal M. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95 (1998) 8892-8897
150. Shults C., Oakes D., Kieburtz K., Beal M., Haas R., Plumb S., et al. Effects of coenzyme Q(10) in early Parkinson disease - Evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
151. Beal M. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S39-S47 discussion S47-S48
152. Du Y., Ma Z., Lin S., Dodel R., Gao F., Bales K., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98 (2001) 14669-14674
153. Wu D., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22 (2002) 1763-1771
154. Tatton W. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8 (1993) S20-S30
155. Waldmeier P., Spooren W., and Hengerer B. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 362 (2000) 526-537
156. Markey S., Johannessen J., Chiueh C., Burns R., and Herkenham M. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311 (1984) 464-467
157. Javitch J., D'Amato R., Strittmatter S., and Snyder S. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82 (1985) 2173-2177
158. Duyckaerts C. Images. Les corps et prolongements de Lewy. Rev Neurol (Paris) 156 (2000) 800-801